Matthew Kaplan

Stock Analyst at Ladenburg Thalmann

(2.81)
# 1,940
Out of 5,033 analysts
26
Total ratings
62.5%
Success rate
18.82%
Average return

Stocks Rated by Matthew Kaplan

United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $319$344
Current: $432.69
Upside: -20.50%
UroGen Pharma
Jun 14, 2024
Maintains: Buy
Price Target: $48$54
Current: $18.00
Upside: +197.30%
TG Therapeutics
May 2, 2024
Maintains: Buy
Price Target: $39$40
Current: $35.12
Upside: +13.90%
Liquidia
Dec 21, 2023
Maintains: Buy
Price Target: $15$30
Current: $24.44
Upside: +22.75%
Ardelyx
Aug 3, 2023
Maintains: Buy
Price Target: $7.5$8.5
Current: $5.10
Upside: +66.67%
Avadel Pharmaceuticals
May 2, 2023
Maintains: Buy
Price Target: $15$16
Current: $15.80
Upside: +1.27%
Kiora Pharmaceuticals
Feb 8, 2023
Reiterates: Buy
Price Target: $1,071
Current: $2.55
Upside: +41,900.00%
Beyond Air
Jun 29, 2022
Maintains: Buy
Price Target: $340$460
Current: $2.44
Upside: +18,752.46%
Lipocine
Dec 10, 2020
Upgrades: Buy
Price Target: $51
Current: $2.93
Upside: +1,640.61%
Cogent Biosciences
Oct 14, 2020
Initiates: Buy
Price Target: $16
Current: $16.22
Upside: -1.36%
Initiates: Buy
Price Target: $45
Current: $5.56
Upside: +709.35%